The increased risk of germline PALB2 pathogenic/likely pathogenic (P/LP) variants for breast cancer was initially suggested in 2007, and it was regarded as the third most significant breast cancer gene after BRCA1 and BRCA2 following the publication by Antoniou et al. about its breast cancer risk estimate that seemed to overlap with BRCA2 [5,6]. This evidence concerns the gene PALB2 and breast carcinoma.